Lomatium dissectum Inhibits Secretion of CXCL10, a Chemokine Associated with Poor Prognosis in Highly Pathogenic Influenza A Infection
David Zamechek
Cynthia A Wenner
PDF
HTML

Keywords

Lomatium dissectum
CXCL10
Influenza
Immune modulation
PDF
HTML

Abstract

Objective: Lomatium dissectum is a plant native to the Western US traditionally used in the Native American culture to treat influenza, which remains a persistent threat to human health. Evidence suggests that dysregulation of cytokines and chemokines, including CXCL10, is the primary factor leading to poor prognosis in highly pathogenic influenza infection. This study was conducted to address the hypothesis that an aqueous extract of L. dissectum root inhibits CXCL10 secretion by human bronchial epithelial cells stimulated with polyinosinic:polycytidylic acid (poly i:c), a synthetic analog of viral dsRNA.

Design: BEAS-2B cells treated with poly i:c were exposed to L. dissectum root aqueous extract simultaneously or at 2 h intervals up to 8 h post-stimulation. Supernatants were harvested at 24 h and enzyme-linked immunosorbent assay (ELISA) performed to determine CXCL10 concentrations.

Results: L. dissectum root aqueous extract at 1 µg/mL significantly inhibited CXCL10 secretion (P=0.043, Anova, Tukey HSD) and demonstrated maximal inhibition 6 h post poly i:c exposure. MTT cytotoxicity assay results suggest that this inhibitory effect was not due to extract-induced cytotoxicity.

Conclusion: The observation that L. dissectum extract inhibits CXCL10 secretion provides a plausible mechanism for the efficacy of L. dissectum in influenza treatment reported in ethnobotanical studies and case reports. L. dissectum may reduce morbidity and mortality associated with influenza and merits further research.

PDF
HTML

References

Maines TR, Szretter KJ, Perrone L, et al. Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response.Immunol Rev. 2008; 225:68–84.
Webster RG. Influenza: an emerging disease. Emerging Infectious Diseases; Volume 4 Number 3: A special issue from the National Center for Infectious Disease on the origin, history and development of pandemic influenza]. [Internet]. [12/29/2005:5/10/2009] .
WHO. World Health Organization Epidemic and Pandemic Alert and Response. Pandemic Flu Frequently asked questions. [Internet]. [5/2/2009:5/18/2009] .
Webby RJ, Webster RG. Are we ready for pandemic influenza? Science. 2003; 302(5650):1519–22.
Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against pandemic influenza. Immunity. 2006; 24(1):5–9.
WHO. Pandemic influenza vaccines: current status [Internet] [9/24/2009;10/28/2009]. .
Guralnik M, Rosenbloom RA, Petteruti MP, Lefante C. Limitations of current prophylaxis against influenza virus infection. Am J Ther. 2007; 14(5):449–54.
Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis. 2006; 194(Suppl 2):S119–26.
Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med. 2009; 6(5):e1000085.
CDC. Background: Interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) viruses, 2008-09 Influenza Season [Internet]. [12/12/2009; 4/13/2010] .
CDC. Weekly Influenze Surveillance Report [Internet]. [11/7/2011;6/4/2009] .
Santibanez S, Fiore AE, Merlin TL, Redd S. A primer on strategies for prevention and control of seasonal and pandemic influenza. Am J Public Health. 2009; 99(Suppl 2):S216–24.
de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006; 12(10):1203–7.
Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet. 2004; 363(9409):617–9.
Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, et al. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci USA. 2009; 106(9):3455–60.
Cameron CM, Cameron MJ, Bermejo-Martin JF, et al. Gene expression analysis of host innate immune responses during Lethal H5N1 infection in ferrets. J Virol. 2008; 82(22):11308–17.
Kobasa D, Jones SM, Shinya K, et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature. 2007; 445(7125):319–23.
Jassim SA, Naji MA. Novel antiviral agents: a medicinal plant perspective. J Appl Microbiol. 2003; 95(3):412–27.
Weinstock DM, Zuccotti G. The evolution of influenza resistance and treatment. J Am Med Assoc. 2009; 301(10):1066–9.
Moore M. Medicinal Plants of the Pacific West, 1st edn. Santa Fe: Red Crane Books; 1993.
NaturalStandard. Lomatium Professional Monograph [Internet]. [6/4/2009] .
Chamberlin RV. The Ethno-botany of the Gosiute Indians of Utah. Lancaster, Pa.: The New era printing company; 1911.
Moerman DE. Medicinal Plants of Native America. Ann Arbor: Museum of Anthropology, University of Michigan; 1986.
Moerman DE. Native American Ethnobotany. Portland, Or.: Timber Press; 1998.
Turner NJ, Royal British Columbia Museum. Thompson Ethnobotany: Knowledge and Usage of Plants by the Thompson Indians of British Columbia. Victoria: Royal British Columbia Museum; 1990.
Krebbs E. Indian remedy for influenza. In: Editor GR, ed. Bulletin of the Nevada State Board of Health, Carson City, Nevada; 1920.
Mitchell WA, Bastyr JB. Plant Medicine in Practice: Using the Teachings of John Bastyr. St. Louis, Mo.: Churchill Livingstone; 2003.
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.Nature. 2001; 413(6857):732–8.
Guillot L, Le Goffic R, Bloch S, et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem. 2005; 280(7):5571–80.
Matsukura S, Kokubu F, Kurokawa M, et al. Synthetic double-stranded RNA induces multiple genes related to inflammation through Toll-like receptor 3 depending on NF-kappaB and/or IRF-3 in airway epithelial cells. Clin Exp Allergy. 2006; 36(8):1049–62.
Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009; 227(1):75–86.
Xagorari A, Chlichlia K. Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol J. 2008; 2:49–59.
Taima K, Imaizumi T, Yamashita K, et al. Expression of IP-10/CXCL10 is upregulated by double-stranded RNA in BEAS-2B bronchial epithelial cells. Respiration. 2006; 73(3):360–4.
Kato A, Truong-Tran AQ, Scott AL, Matsumoto K, Schleimer RP. Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-beta-dependent mechanism. J Immunol. 2006; 177(10):7164–72.
Song M, Kim YJ, Ryu JC. Phospholipidosis induced by PPARgamma signaling in human bronchial epithelial (BEAS-2B) cells exposed to amiodarone. Toxicol Sci. 2011; 120(1):98–108.
Askarieh G, Alsio A, Pugnale P, et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology. 2010; 51(5):1523–30.
Falconer K, Askarieh G, Weis N, Hellstrand K, Alaeus A, Lagging M. IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV. Scand J Infect Dis. 2010; 42(11–12):896–901.
Katoh S, Fukushima K, Matsumoto N, et al. Accumulation of CXCR3-expressing eosinophils and increased concentration of its ligands (IP10 and Mig) in bronchoalveolar lavage fluid of patients with chronic eosinophilic pneumonia. Int Arch Allergy Immunol. 2005; 137(3):229–35.
Turner JE, Steinmetz OM, Stahl RA, Panzer U. Targeting of Th1-associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for inflammatory diseases. Mini Rev Med Chem. 2007; 7(11):1089–96.
Tang NL, Chan PK, Wong CK, et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem. 2005; 51(12):2333–40.
VanWagenen BC, Huddleston J, Cardellina JH, 2nd. Native American food and medicinal plants, 7. Antimocrobial Tetronic Acids From Lomatium dissectum. J Nat Prod. 1986; 42(4):1117–22.
VanWagenen BC, Huddleston J, Cardellina JH, 2nd. Native American food and medicinal plants, 8. Water-soluble constituents of Lomatium dissectum. J Nat Prod. 1988; 51(1):136–41.
Carlson HJ, Douglas HG. Antibiotic agents separated from the root of lace-leaved Leptotaenia. J Bacteriol. 1948; 55(5):615–21.
McCutcheon AR, Ellis SM, Hancock RE, Towers GH. Antibiotic screening of medicinal plants of the British Columbian native peoples. J Ethnopharmacol. 1992; 37(3):213–23.
Moerman DE. Native American Medicinal Plants: An Ethnobotanical Dictionary. Portland, OR: Timber Press; 2009.
USDA. Lomatium Dissectum Plant Profile. [Internet]. [1/28/2011;9/8/2013] http://plants.usda.gov/core/profile?symbol=LODI.
UPS UPS. Species At-Risk. [Internet]. [5/08/2012;9/7/2013] http://www.unitedplantsavers.org/content.php/121-species-at-risk

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.